Table 3.
Summary of Glasgow Royal Infirmary studies
| Study | Year | Patient no. | Years incl. | Additional incl. & excl. criteria | Inflammatory marker | Measurement intervals | Minimum follow-up |
|---|---|---|---|---|---|---|---|
| McMillan et al [10] | 2003 | 174 | 1993–1998 | Curative resection of CRC, staged by Dukes | CRP | Preoperative 4 mo postoperative |
Unclear |
| Canna et al [33] | 2005 | 147 | 1997–2001 | Curative resection of Dukes B or C CRC | CRP | Preoperative | 30 mo |
| Carruthers et al [38] | T3 and T4 borderline or unresectable rectal cancer having preoperative chemoradiotherapy. | NLR, PLR, albumin, CEA | Preradiotherapy | 0.5 mo | |||
| Crozier et al [34] | 2007 | 180 | 1999–2004 | Curative resection of CRC. Excludes any emergency cases, preoperative radiotherapy, clinical infection, and inflammatory conditions | CRP | Preoperative Day 2 postoperative |
22 mo |
| Crozier et al [35] | 2009 | 188 | 1999–2006 | Curative resection of CRC, preoperative CRP and albumin available | mGPS | Preoperative | 12 mo |
| Roxburgh et al [12] | 2009 | 287 | 1997–2004 | Curative resection of CRC. Excludes emergency presentation, infection, chronic inflammatory conditions, preoperative radiotherapy | GPS | Preoperative | 34 mo |
| Proctor et al [36] | 2011 | 27,031 | 2000–2007 | Patients with any cancer, as identified in the Scottish Cancer Registry that had blood tests recorded any time before diagnosis | CRP, albumin, white cell count (WCC), neutrophils, LMR, PLR, mGPS, NLR, PI | Variable | Unclear |
| Richards et al [37] | 2012 | 343 | 1997–2007 | Stage I–III CRC | mGPS | Preoperative | 45 mo |